Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 50mg ; 200mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - chlordiazepoxide hydrochloride - oral capsule - 5mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - caffeine; phenylephrine hydrochloride; paracetamol - oral capsule - 25mg ; 6.1mg ; 500mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - phenylephrine hydrochloride; paracetamol; guaifenesin - oral capsule - 6.1mg ; 500mg ; 100mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules (la) are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of methylphenidate hydrochloride extended-release capsules (la) in the treatment of adhd was established in 1 controlled trial of children aged 6 to 12 who met dsm-iv criteria for adhd (see clinical pharmacology ). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - trazodone hydrochloride - oral capsule - 50mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - trazodone hydrochloride - oral capsule - 100mg

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; docusate sodium; iron oxide red; calcium hydrogen phosphate; magnesium stearate; ethylcellulose; mannitol - parkinson's disease and parkinsonian symptoms including post- encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - paracetamol, quantity: 500 mg; pseudoephedrine hydrochloride, quantity: 30 mg - tablet, uncoated - excipient ingredients: stearic acid; povidone; purified talc; sodium benzoate; pregelatinised maize starch; maize starch - for the temporary relief of sinus congestion and pain, nasal congestion and runny nose.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - capsule, hard - excipient ingredients: indigo carmine; purified talc; gelatin; iron oxide red; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.